CMMB
Chemomab Therapeutics Ltd.
A clinical-stage biotechnology company developing antibody therapies for fibro-inflammatory diseases—conditions that combine inflammation with tissue scarring. Its lead drug, nebokitug, targets a protein called CCL24 to treat liver and skin conditions like primary sclerosing cholangitis. Founded in 2011 by scientist Adi Mor, the company's name blends "chemokine" (its target protein family) with "-mab," the standard suffix for monoclonal antibodies.
ADRUnderlying: CMMBCUSIP: 16385C104HealthcareIL2 holders
Sponsored American Depositary Shares (ADS)
Total Value
$5.18M
Total Shares
371.8K
Net Share Change
+371.8K
Activity
2 buying
Investor
Value
Shares
Weight
Change
